The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

BACKGROUND: The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated receptors in t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cardiovasc Diabetol
Autori principali: Leonard, Charles E., Brensinger, Colleen M., Dawwas, Ghadeer K., Deo, Rajat, Bilker, Warren B., Soprano, Samantha E., Dhopeshwarkar, Neil, Flory, James H., Bloomgarden, Zachary T., Gagne, Joshua J., Aquilante, Christina L., Kimmel, Stephen E., Hennessy, Sean
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041286/
https://ncbi.nlm.nih.gov/pubmed/32098624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-00999-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi